Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Understanding the impact of the microbiome on critical illness syndromes
FY 2022-23
Summary
The microbiome is the complex ecosystem of all microbes on and in the human body, the majority of which are found in the large bowel. There is a complex interplay between the gut microbiome and the host, with signals from microbes affecting distant organs, including the lungs. Molecules with important anti-inflammatory and immune altering effects are produced only by specific microbes or groups of microbes. These include bile acids, and short chain fatty acids (SCFAs). During critical illness, there is a severe decrease in healthy microbes and an increase in harmful bacteria which often dominate. Our suspicion is that this loss of healthy microbes leads to increased leakiness of the gut and detrimental effects worsening lung health during critical illness. We have two goals: the first is to use plasma (a part of the blood without cells) to identify signatures of disrupted gut microbiome and an unhealthy gut; the second is to assess whether these markers are associated with increased rates of death or time on life support during critical illness. We will do this using a combination of studying large publicly available data to identify markers and then collect human samples to confirm their usefulness in critical illness. This hopefully will allow us to use blood samples to find patients with an abnormal microbiome (an unhealthy gut) and selectively intervene on these patients to restore the normal diversity in their microbiome to improve gut and overall health during critical illness.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486296
Name
Kain Taylor
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding the impact of the microbiome on critical illness syndromes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Respiratory Distress Syndrome; Bile Acid Metabolism; Critical Illness; Gut Epithelial Integrity; Hypoxemic Respiratory Failure; Microbiome; Modelling; Peripheral Biomarkers; Sepsis; Short Chain Fatty Acid Production
Abstract
The microbiome is the complex ecosystem of all microbes on and in the human body, the majority of which are found in the large bowel. There is a complex interplay between the gut microbiome and the host, with signals from microbes affecting distant organs, including the lungs. Molecules with important anti-inflammatory and immune altering effects are produced only by specific microbes or groups of microbes. These include bile acids, and short chain fatty acids (SCFAs). During critical illness, there is a severe decrease in healthy microbes and an increase in harmful bacteria which often dominate. Our suspicion is that this loss of healthy microbes leads to increased leakiness of the gut and detrimental effects worsening lung health during critical illness. We have two goals: the first is to use plasma (a part of the blood without cells) to identify signatures of disrupted gut microbiome and an unhealthy gut; the second is to assess whether these markers are associated with increased rates of death or time on life support during critical illness. We will do this using a combination of studying large publicly available data to identify markers and then collect human samples to confirm their usefulness in critical illness. This hopefully will allow us to use blood samples to find patients with an abnormal microbiome (an unhealthy gut) and selectively intervene on these patients to restore the normal diversity in their microbiome to improve gut and overall health during critical illness.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kain, Taylor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~